Literature DB >> 18988884

Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.

Jennifer E Amengual, Xinmin Zhang, Sherif Ibrahim, Lawrence B Gardner.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18988884     DOI: 10.1182/blood-2008-06-162289

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.

Authors:  A Re; G Gini; M Rupolo; A Levis; A Bandera; A M Liberati; P Tozzi; C Cattaneo; S Casari; C Skert; C Bocci; M Spina; B Allione; L Verga; M Michieli; C Almici; P F Leali; U Tirelli; G Rossi
Journal:  Bone Marrow Transplant       Date:  2017-10-09       Impact factor: 5.483

Review 2.  Regression of HIV-associated grade IV T cell lymphoma with combined antiretroviral therapy only.

Authors:  Y K O Teng; E F Schippers; P W Wijermans
Journal:  Int J Hematol       Date:  2011-05-11       Impact factor: 2.490

Review 3.  How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.

Authors:  Satish Gopal; Thomas G Gross
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

4.  Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.

Authors:  Markus Hecht; Sonja Erber; Thomas Harrer; Hartwig Klinker; Thomas Roth; Hans Parsch; Nora Fiebig; Rainer Fietkau; Luitpold V Distel
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

5.  Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation.

Authors:  Markus Hecht; Thomas Harrer; Verena Körber; Eric O Sarpong; Fabian Moser; Nora Fiebig; Manuela Schwegler; Michael Stürzl; Rainer Fietkau; Luitpold V Distel
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.